nach oben

European Archives of Psychiatry and Clinical Neuroscience

Erschienen in:

10.11.2020 | Original Paper

Characteristics associated with self-reported medication adherence in persons with psychosis referred to psychosocial rehabilitation centers

verfasst von: Hélène Verdoux, Clélia Quiles, Laura Bon, Isabelle Chéreau-Boudet, Julien Dubreucq, Emilie Legros-Lafarge, Nathalie Guillard-Bouhet, Catherine Massoubre, Julien Plasse, Nicolas Franck

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience | Ausgabe 8/2021

Einloggen, um Zugang zu erhalten

Abstract

The aim of the present study was to explore the characteristics of psychotropic treatment and of psychosocial functioning associated with self-reported medication adherence in persons with psychosis engaged in rehabilitation. The study was performed in the REHABase cohort including persons referred to a French network of psychosocial rehabilitation centers. Treatment adherence was assessed using the Medication Adherence Rating Scale (MARS). The associations between MARS score (categorized as “low” < 7 vs. “high” ≥ 7) and functioning or psychotropic treatment characteristics were explored using multivariate analyses in 326 participants with schizophrenia spectrum disorders. Regarding psychotropic treatment, high anticholinergic load was the only characteristic associated with poor medication adherence (adjusted OR, aOR 1.98, 95% CI 1.07–3.66). Regarding functioning measures, participants with poor medication adherence were more likely to present with lower stage of recovery (aOR 2.38, 95% CI 1.31–4.32), poor quality of life (aOR 2.17, 95% CI 1.27–3.71), mental well-being (aOR 1.68, 95% CI 1.03–2.72) and self-esteem (aOR 1.74, 95% CI 1.05–2.87), and higher internalized stigma (aOR 1.88, 95% CI 1.09–3.23). Self-reported poor medication adherence is a marker of poor functioning in persons with psychosis. The MARS is a quick and simple measure of adherence that may be helpful in clinical and rehabilitation settings to identify persons with specific rehabilitation needs.

Law H, Morrison AP (2014) Recovery in psychosis: a Delphi study with experts by experience. Schizophr Bull 40:1347–1355. https://doi.org/10.1093/schbul/sbu047CrossRefPubMedPubMedCentral

Mohamed S, Rosenheck R, McEvoy J, Swartz M, Stroup S, Lieberman JA (2009) Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophr Bull 35:336–346. https://doi.org/10.1093/schbul/sbn067CrossRefPubMed

Leucht S, Heres S (2006) Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry 67(Suppl 5):3–8PubMed

Verdoux H, Lengronne J, Liraud F, Gonzales B, Assens F, Abalan F, van Os J (2000) Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects. Acta Psychiatr Scand 102:203–210. https://doi.org/10.1034/j.1600-0447.2000.102003203.xCrossRefPubMed

Goff DC, Hill M, Freudenreich O (2010) Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder. J Clin Psychiatry 71(Suppl 2):20–26. https://doi.org/10.4088/JCP.9096su1cc.04CrossRefPubMed

Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, Davis JM (2012) Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 379:2063–2071. https://doi.org/10.1016/S0140-6736(12)60239-6CrossRefPubMed

Velligan DI, Lam YW, Glahn DC, Barrett JA, Maples NJ, Ereshefsky L, Miller AL (2006) Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull 32:724–742. https://doi.org/10.1093/schbul/sbj075CrossRefPubMedPubMedCentral

Velligan DI, Maples NJ, Pokorny JJ, Wright C (2020) Assessment of adherence to oral antipsychotic medications: what has changed over the past decade? Schizophr Res 215:17–24. https://doi.org/10.1016/j.schres.2019.11.022CrossRefPubMed

Garcia S, Martinez-Cengotitabengoa M, Lopez-Zurbano S, Zorrilla I, Lopez P, Vieta E, Gonzalez-Pinto A (2016) Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: a systematic review. J Clin Psychopharmacol 36:355–371. https://doi.org/10.1097/JCP.0000000000000523CrossRefPubMedPubMedCentral

10.

Cramer JA, Rosenheck R (1998) Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 49:196–201. https://doi.org/10.1176/ps.49.2.196CrossRefPubMed

11.

Kane JM, Kishimoto T, Correll CU (2013) Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry 12:216–226. https://doi.org/10.1002/wps.20060CrossRefPubMedPubMedCentral

12.

Barbui C, Kikkert M, Mazzi MA, Becker T, Bindman J, Schene A, Nose M, Helm H, Thornicroft G, Tansella M (2009) Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence. Psychopathology 42:311–317. https://doi.org/10.1159/000232973CrossRefPubMed

13.

Stirratt MJ, Dunbar-Jacob J, Crane HM, Simoni JM, Czajkowski S, Hilliard ME, Aikens JE, Hunter CM, Velligan DI, Huntley K, Ogedegbe G, Rand CS, Schron E, Nilsen WJ (2015) Self-report measures of medication adherence behavior: recommendations on optimal use. Transl Behav Med 5:470–482. https://doi.org/10.1007/s13142-015-0315-2CrossRefPubMedPubMedCentral

14.

Byerly MJ, Thompson A, Carmody T, Bugno R, Erwin T, Kashner M, Rush AJ (2007) Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia. Psychiatr Serv 58:844–847. https://doi.org/10.1176/ps.2007.58.6.844CrossRefPubMed

15.

Jonsdottir H, Opjordsmoen S, Birkenaes AB, Engh JA, Ringen PA, Vaskinn A, Aamo TO, Friis S, Andreassen OA (2010) Medication adherence in outpatients with severe mental disorders: relation between self-reports and serum level. J Clin Psychopharmacol 30:169–175. https://doi.org/10.1097/JCP.0b013e3181d2191eCrossRefPubMed

16.

Fialko L, Garety PA, Kuipers E, Dunn G, Bebbington PE, Fowler D, Freeman D (2008) A large-scale validation study of the Medication Adherence Rating Scale (MARS). Schizophr Res 100:53–59. https://doi.org/10.1016/j.schres.2007.10.029CrossRefPubMed

17.

Lien YJ, Chang HA, Kao YC, Tzeng NS, Lu CW, Loh CH (2018a) The impact of cognitive insight, self-stigma, and medication compliance on the quality of life in patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci 268:27–38. https://doi.org/10.1007/s00406-017-0829-3CrossRefPubMed

18.

Freudenreich O, Cather C, Evins AE, Henderson DC, Goff DC (2004) Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. J Clin Psychiatry 65:1372–1376. https://doi.org/10.4088/jcp.v65n1012CrossRefPubMed

19.

Puschner B, Angermeyer MC, Leese M, Thornicroft G, Schene A, Kikkert M, Burti L, Tansella M, Becker T (2009) Course of adherence to medication and quality of life in people with schizophrenia. Psychiatry Res 165:224–233. https://doi.org/10.1016/j.psychres.2007.10.011CrossRefPubMed

20.

Franck N, Bon L, Dekerle M, Plasse J, Massoubre C, Pommier R, Legros-Lafarge E, Jaafari N, Guillard-Bouhet N, Quiles C, Couhet G, Verdoux H, Gouache B, Martin B, Cervello S, Demily C, Dubreucq J (2019) Satisfaction and needs in serious mental illness and autism spectrum disorder: the REHABase psychosocial rehabilitation project. Psychiatr Serv 70:316–323. https://doi.org/10.1176/appi.ps.201800420CrossRefPubMed

21.

Verdoux H, Quiles C, Cervello S, Dubreucq J, Bon L, Massoubre C, Pommier R, Legros-Lafarge E, Jaafari N, Guillard-Bouhet N, Chereau-Boudet I, Couhet G, Plasse J, Franck N (2019) Functioning and cognitive characteristics of clozapine users referred to psychosocial rehabilitation centers: a REHABase cohort study. Psychiatry Res 281:112543. https://doi.org/10.1016/j.psychres.2019.112543CrossRefPubMed

22.

American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edn. Arlington

23.

Thompson K, Kulkarni J, Sergejew AA (2000) Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res 42:241–247CrossRefPubMed

24.

Misdrahi D, Verdoux H, Llorca PM, Bayle FJ (2004) Therapeutic adherence and schizophrenia: the interest of the validation of the French translation of Medication Adherence Rating Scale (MARS). Encephale 30:409–410PubMed

25.

Fond G, Boyer L, Boucekine M, Aden LA, Schurhoff F, Tessier A, Andrianarisoa M, Berna F, Brunel L, Capdevielle D, Chereau I, Mallet J, Denizot H, Dorey JM, Dubertret C, Dubreucq J, Faget C, Gabayet F, Rey R, Richieri R, Passerieux C, Schandrin A, Urbach M, Vidailhet P, Llorca PM, Misdrahi D, group F-S (2017) Validation study of the Medication Adherence Rating Scale. Results from the FACE-SZ national dataset. Schizophr Res 182:84–89. https://doi.org/10.1016/j.schres.2016.10.023CrossRefPubMed

26.

Misdrahi D, Tessier A, Swendsen J, Berna F, Brunel L, Capdevielle D, Chereau I, Danion JM, De Pradier M, Dorey JM, Dubertret C, Dubreucq J, Faget C, Gabayet F, Rey R, Richieri R, Passerieux C, Schandrin A, Schurhoff F, Tronche AM, Urbach M, Llorca PM, Fond G (2016) Determination of adherence profiles in schizophrenia using self-reported adherence: results from the FACE-SZ dataset. J Clin Psychiatry 77:e1130–e1136. https://doi.org/10.4088/JCP.15m10115CrossRefPubMed

27.

Verdoux H, Quiles C, Bon L, Chereau-Boudet I, Dubreucq J, Fiegi L, Guillard-Bouhet N, Massoubre C, Plasse J, Franck N (2020) Impact of anticholinergic load on functioning and cognitive performances of persons with psychosis referred to psychosocial rehabilitation centers. Psychol Med. https://doi.org/10.1017/S0033291720001403CrossRefPubMed

28.

Salahudeen MS, Duffull SB, Nishtala PS (2015) Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. BMC Geriatr 15:31. https://doi.org/10.1186/s12877-015-0029-9CrossRefPubMedPubMedCentral

29.

Duran CE, Azermai M, Vander Stichele RH (2013) Systematic review of anticholinergic risk scales in older adults. Eur J Clin Pharmacol 69:1485–1496. https://doi.org/10.1007/s00228-013-1499-3CrossRefPubMed

30.

Guy W (1976) ECDEU assessment manual for psychopharmacology. Department of Health, Education, and Welfare, Rockville

31.

American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn. Text Revision (DSM-IV-TR). Washington, DC

32.

Andresen R, Caputi P, Oades L (2006) Stages of recovery instrument: development of a measure of recovery from serious mental illness. Aust N Z J Psychiatry 40:972–980. https://doi.org/10.1080/j.1440-1614.2006.01921.xCrossRefPubMed

33.

Boyer L, Simeoni MC, Loundou A, D’Amato T, Reine G, Lancon C, Auquier P (2010) The development of the S-QoL 18: a shortened quality of life questionnaire for patients with schizophrenia. Schizophr Res 121:241–250. https://doi.org/10.1016/j.schres.2010.05.019CrossRefPubMed

34.

Tennant R, Hiller L, Fishwick R, Platt S, Joseph S, Weich S, Parkinson J, Secker J, Stewart-Brown S (2007) The Warwick-Edinburgh Mental Well-being Scale (WEMWBS): development and UK validation. Health Qual Life Outcomes 5:63. https://doi.org/10.1186/1477-7525-5-63CrossRefPubMedPubMedCentral

35.

Trousselard M, Steiler D, Dutheil F, Claverie D, Canini F, Fenouillet F, Naughton G, Stewart-Brown S, Franck N (2016) Validation of the Warwick-Edinburgh Mental Well-Being Scale (WEMWBS) in French psychiatric and general populations. Psychiatry Res 245:282–290. https://doi.org/10.1016/j.psychres.2016.08.050CrossRefPubMed

36.

Ritsher JB, Otilingam PG, Grajales M (2003) Internalized stigma of mental illness: psychometric properties of a new measure. Psychiatry Res 121:31–49CrossRefPubMed

37.

Brohan E, Gauci D, Sartorius N, Thornicroft G, Group GA-ES (2011) Self-stigma, empowerment and perceived discrimination among people with bipolar disorder or depression in 13 European countries: the GAMIAN-Europe study. J Affect Disord 129:56–63. https://doi.org/10.1016/j.jad.2010.09.001CrossRefPubMed

38.

Rosenberg M (1965) Society and the adolescent self-image. Princeton University Press, Princeton

39.

Vallieres E, Vallerand AL (1990) Traduction et validation canadienne française de l’échelle de l’estime de soi de Rosenberg. Int J Psychol 25:305–316CrossRef

40.

Birchwood M, Smith J, Drury V, Healy J, Macmillan F, Slade M (1994) A self-report Insight Scale for psychosis: reliability, validity and sensitivity to change. Acta Psychiatr Scand 89:62–67CrossRefPubMed

41.

Jonsdottir H, Opjordsmoen S, Birkenaes AB, Simonsen C, Engh JA, Ringen PA, Vaskinn A, Friis S, Sundet K, Andreassen OA (2013) Predictors of medication adherence in patients with schizophrenia and bipolar disorder. Acta Psychiatr Scand 127:23–33. https://doi.org/10.1111/j.1600-0447.2012.01911.xCrossRefPubMed

42.

Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, Docherty JP, Expert Consensus Panel on Adherence Problems in S, Persistent Mental I (2009) The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 70(Suppl 4):1–46 (quiz 47–48)PubMed

43.

Nielsen J, Munk-Jorgensen P, Skadhede S, Correll CU (2011) Determinants of poor dental care in patients with schizophrenia: a historical, prospective database study. J Clin Psychiatry 72:140–143. https://doi.org/10.4088/JCP.09m05318yelCrossRefPubMed

44.

Cicala G, Barbieri MA, Spina E, de Leon J (2019) A comprehensive review of swallowing difficulties and dysphagia associated with antipsychotics in adults. Exp Rev Clin Pharmacol 12:219–234. https://doi.org/10.1080/17512433.2019.1577134CrossRef

45.

Cohen D (2017) Clozapine and gastrointestinal hypomotility. CNS Drugs 31:1083–1091. https://doi.org/10.1007/s40263-017-0481-5CrossRefPubMed

46.

Verdoux H, Pambrun E, Tournier M, Cortaredona S, Verger P (2019) Multi-trajectories of antidepressant and antipsychotic use: a 11-year naturalistic study in a community-based sample. Acta Psychiatr Scand 139:536–547. https://doi.org/10.1111/acps.13020CrossRefPubMed

47.

Tiihonen J, Mittendorfer-Rutz E, Torniainen M, Alexanderson K, Tanskanen A (2016) Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study. Am J Psychiatry 173:600–606. https://doi.org/10.1176/appi.ajp.2015.15050618CrossRefPubMed

48.

Yaegashi H, Kirino S, Remington G, Misawa F, Takeuchi H (2020) Adherence to oral antipsychotics measured by electronic adherence monitoring in schizophrenia: a systematic review and meta-analysis. CNS Drugs 34:579–598. https://doi.org/10.1007/s40263-020-00713-9CrossRefPubMed

49.

Sendt KV, Tracy DK, Bhattacharyya S (2015) A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders. Psychiatry Res 225:14–30. https://doi.org/10.1016/j.psychres.2014.11.002CrossRefPubMed

50.

Acosta FJ, Hernandez JL, Pereira J, Herrera J, Rodriguez CJ (2012) Medication adherence in schizophrenia. World J Psychiatry 2:74–82. https://doi.org/10.5498/wjp.v2.i5.74CrossRefPubMedPubMedCentral

51.

Moritz S, Berna F, Jaeger S, Westermann S, Nagel M (2017) The customer is always right? Subjective target symptoms and treatment preferences in patients with psychosis. Eur Arch Psychiatry Clin Neurosci 267:335–339. https://doi.org/10.1007/s00406-016-0694-5CrossRefPubMed

52.

Uhlmann C, Kaehler J, Harris MS, Unser J, Arolt V, Lencer R (2014) Negative impact of self-stigmatization on attitude toward medication adherence in patients with psychosis. J Psychiatr Pract 20:405–410. https://doi.org/10.1097/01.pra.0000454787.75106.aeCrossRefPubMed

53.

Feldhaus T, Falke S, von Gruchalla L, Maisch B, Uhlmann C, Bock E, Lencer R (2018) The impact of self-stigmatization on medication attitude in schizophrenia patients. Psychiatry Res 261:391–399. https://doi.org/10.1016/j.psychres.2018.01.012CrossRefPubMed

54.

Lien YJ, Chang HA, Kao YC, Tzeng NS, Lu CW, Loh CH (2018b) Insight, self-stigma and psychosocial outcomes in Schizophrenia: a structural equation modelling approach. Epidemiol Psychiatr Sci 27:176–185. https://doi.org/10.1017/S2045796016000950CrossRefPubMed

55.

Caqueo-Urizar A, Urzua A, Habib J, Loundou A, Boucekine M, Boyer L, Fond G (2019) Relationships between social stigma, stigma experience and self-stigma and impaired quality of life in schizophrenia across three Latin-American countries. Eur Arch Psychiatry Clin Neurosci. https://doi.org/10.1007/s00406-019-01035-8CrossRefPubMed

56.

Drake RJ, Nordentoft M, Haddock G, Arango C, Fleischhacker WW, Glenthoj B, Leboyer M, Leucht S, Leweke M, McGuire P, Meyer-Lindenberg A, Rujescu D, Sommer IE, Kahn RS, Lewis SW (2015) Modeling determinants of medication attitudes and poor adherence in early nonaffective psychosis: implications for intervention. Schizophr Bull 41:584–596. https://doi.org/10.1093/schbul/sbv015CrossRefPubMedPubMedCentral

57.

Dubreucq J, Plasse J, Gabayet F, Faraldo M, Blanc O, Chereau I, Cervello S, Couhet G, Demily C, Guillard-Bouhet N, Gouache B, Jaafari N, Legrand G, Legros-Lafarge E, Pommier R, Quiles C, Straub D, Verdoux H, Vignaga F, Massoubre C, Network RE, Franck N (2020) Self-stigma in serious mental illness and autism spectrum disorder: results from the REHABase national psychiatric rehabilitation cohort. Eur Psychiatry 63:e13. https://doi.org/10.1192/j.eurpsy.2019.12CrossRefPubMedPubMedCentral

58.

Gaebel W, Zaske H, Hesse K, Klingberg S, Ohmann C, Grebe J, Kolbe H, Icks A, Schneider F, Backes V, Wolff-Menzler C, Guse B, Gallinat J, Bock T, Jockers-Scherubl MC, Kruger T, Jessen F, Bechdolf A, Kircher T, Konrad C, Falkai P, Schaub A, Rudolph M, Kollner V, Schmid-Ott G, Linden M, Lieberei B, Stuhlinger M, Sommerfeld S, Schumacher A, Krenge S, Gereke S, Monter N, Navarro-Urena A, Frosch G, Kuhlbusch FJ, Cleveland H, Riesbeck M (2019) Promoting stigma coping and empowerment in patients with schizophrenia and depression: results of a cluster-RCT. Eur Arch Psychiatry Clin Neurosci. https://doi.org/10.1007/s00406-019-01064-3CrossRefPubMed

Titel: Characteristics associated with self-reported medication adherence in persons with psychosis referred to psychosocial rehabilitation centers
verfasst von: Hélène Verdoux
Clélia Quiles
Laura Bon
Isabelle Chéreau-Boudet
Julien Dubreucq
Emilie Legros-Lafarge
Nathalie Guillard-Bouhet
Catherine Massoubre
Julien Plasse
Nicolas Franck
Publikationsdatum: 10.11.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: European Archives of Psychiatry and Clinical Neuroscience / Ausgabe 8/2021
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-020-01207-x

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2021

Religiosity and prevalence of suicide, psychiatric disorders and psychotic symptoms in the French general population

Insight-related beliefs and controllability appraisals contribute little to hallucinated voices: a transdiagnostic network analysis study

Palliative and high-intensity end-of-life care in schizophrenia patients with lung cancer: results from a French national population-based study

Increased PLA2 activity in individuals at ultra-high risk for psychosis